Amgen Inc. (NASDAQ:AMGN) Shares Acquired by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale grew its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 767,943 shares of the medical research company's stock after buying an additional 56,296 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.14% of Amgen worth $232,446,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Proficio Capital Partners LLC increased its stake in shares of Amgen by 35.0% during the 4th quarter. Proficio Capital Partners LLC now owns 1,806 shares of the medical research company's stock valued at $471,000 after acquiring an additional 468 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Amgen during the 4th quarter valued at about $1,428,000. AlphaQuest LLC boosted its position in shares of Amgen by 3.9% in the fourth quarter. AlphaQuest LLC now owns 1,993 shares of the medical research company's stock worth $519,000 after acquiring an additional 74 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in Amgen by 14.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 208,167 shares of the medical research company's stock valued at $54,257,000 after purchasing an additional 25,692 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Down 0.2%

Shares of NASDAQ AMGN traded down $0.48 during midday trading on Wednesday, reaching $296.52. 2,097,995 shares of the company's stock were exchanged, compared to its average volume of 2,848,756. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The business's fifty day moving average price is $282.95 and its two-hundred day moving average price is $287.50. The stock has a market capitalization of $159.44 billion, a PE ratio of 27.05, a price-to-earnings-growth ratio of 2.69 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same quarter last year, the firm earned $3.96 EPS. Amgen's quarterly revenue was up 9.4% on a year-over-year basis. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares of the company's stock, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.76% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. Mizuho increased their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $328.00 target price on shares of Amgen in a research report on Friday, June 27th. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Royal Bank Of Canada cut their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Finally, Erste Group Bank cut Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $307.82.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.